TAK · NYSE

Takeda Pharmaceutical (TAK) Stock Price & Fundamentals

$736.74+0.88%+$6.45End-of-day price as of Oct 9, 2026

Sample prices

Prices on this page are generated sample data for development, not real market data, so market cap, P/E and dividend yield are illustrative too. Fundamentals are real, from Takeda Pharmaceutical's SEC filings.

Takeda Pharmaceutical (TAK) closed at $736.74 on Oct 9, 2026, up 0.88% from the previous close of $730.29.

Share price, past year

1Y +25.87%

Daily closing prices

52-week range $566.56 – $736.74.

Monthly closing prices

Last closing price of each month
Date	Close
Oct 9, 2026	$736.74
Sep 30, 2026	$712.25
Aug 31, 2026	$665.04
Jul 31, 2026	$638.35
Jun 30, 2026	$619.56
May 29, 2026	$660.11
Apr 30, 2026	$715.57
Mar 31, 2026	$672.51
Feb 27, 2026	$667.59
Jan 30, 2026	$600.18
Dec 31, 2025	$566.56
Nov 28, 2025	$594.77
Oct 31, 2025	$594.83

Key statistics

Market cap: —
P/E (TTM): —
EPS (TTM): —
Revenue (TTM): —
Net income (TTM): —
Shares outstanding: —
Dividend yield: —
52-week range: $566.56 – $736.74

Market cap, P/E and dividend yield aren't shown for Takeda Pharmaceutical yet: its SEC filings count its ordinary shares, which can differ from the shares traded in the US, and report in Japanese yen.

Financials

Takeda Pharmaceutical reported revenue of ¥4.58T for fiscal 2025, up 7.45% from fiscal 2024.

Figures are in Japanese yen (JPY), as Takeda Pharmaceutical reports them to the SEC.

Takeda Pharmaceutical earned net income of ¥107.93B in fiscal 2025, a net margin of 2.4%.

Fiscal 2025 revenue was the highest in the 9 years shown.

Annual revenue

FY17FY18FY19FY20FY21FY22FY23FY24FY25

Takeda Pharmaceutical annual financials by fiscal year, from SEC filings
Fiscal year	Revenue	Growth	Net income	Net margin	EPS (diluted)	Free cash flow
FY2025ended Mar 31, 2025	¥4.58T	+7.5%	¥107.93B	2.4%	¥67.23	¥856.39B
FY2024ended Mar 31, 2024	¥4.26T	+5.9%	¥144.07B	3.4%	¥91.16	¥540.92B
FY2023ended Mar 31, 2023	¥4.03T	+12.9%	¥317.02B	7.9%	¥201.94	¥836.50B
FY2022ended Mar 31, 2022	¥3.57T	+11.6%	¥230.06B	6.5%	¥145.87	¥999.85B
FY2021ended Mar 31, 2021	¥3.20T	−2.8%	¥376.01B	11.8%	¥238.96	¥899.73B
FY2020ended Mar 31, 2020	¥3.29T	+56.9%	¥44.24B	1.3%	¥28.25	¥542.67B
FY2019ended Mar 31, 2019	¥2.10T	+18.5%	¥135.19B	6.5%	¥139.82	¥250.80B
FY2018ended Mar 31, 2018	¥1.77T	+2.2%	¥186.89B	10.6%	¥237.56	¥310.85B
FY2017ended Mar 31, 2017	¥1.73T	—	¥114.94B	6.6%	¥146.26	¥199.70B

Company profile

Name: Takeda Pharmaceutical Company Limited
Ticker: TAK
Exchange: NYSE
Industry (SEC SIC): Pharmaceutical Preparations
Headquarters: 1-1, Nihonbashi-Honcho 2-Chome, Chuo-Ku, Tokyo, M0 103-8668
SEC CIK: 0001395064

Recent SEC filings

20-FAnnual report for period ending Mar 31, 2026
Jun 17, 2026
20-FAnnual report for period ending Mar 31, 2025
Jun 25, 2025
20-FAnnual report for period ending Mar 31, 2024
Jun 26, 2024
20-FAnnual report for period ending Mar 31, 2023
Jun 28, 2023
20-FAnnual report for period ending Mar 31, 2022
Jun 29, 2022
20-FAnnual report for period ending Mar 31, 2021
Jun 29, 2021
20-FAnnual report for period ending Mar 31, 2020
Jun 24, 2020
20-FAnnual report for period ending Mar 31, 2019
Jun 27, 2019

Frequently asked questions

What is Takeda Pharmaceutical's stock price?

Takeda Pharmaceutical (TAK) closed at $736.74 on Oct 9, 2026, up 0.88% from the previous close of $730.29.

How much revenue does Takeda Pharmaceutical make?

Takeda Pharmaceutical reported revenue of ¥4.58T for fiscal 2025, up 7.45% from fiscal 2024.

Sources and methodology

Fundamentals come from Takeda Pharmaceutical Company Limited's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures